EAC 2024 Update in Allergy, Asthma & Immunology
The 2024 EAC activity will provide conference attendees with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology. In addition to a didactic review of relevant guidelines and recent clinical studies, the format will incorporate problem-based learning (PBL), uniquely designed to interface with lectures in context to the core issues relevant to the cases. By means of active discussion, learners will be challenged to formulate and justify medical decision-making concerning diagnostic and treatment strategies for patients. Topics of discussion will include immunodeficiency, biologics for allergic diseases, allergy immunotherapy, mastocytosis, asthma, atopic dermatitis, HAE, and PIDD.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 16.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 16.75 contact hours.
Commercial Support
This activity is supported in part by an independent medical education grant from BioCryst .
Target Audience
Practicing allergists
Allied health professionals
Learning Objectives
At the conclusion of this activity, participants should be able to:
• Outline an endotype, phenotype, and updated guideline-based approach to the treatment of asthma
• Diagnose and manage hereditary angioedema
• Discuss current allergy immunotherapy treatment outcomes, guidelines and regulations for respiratory allergies
• Outline an approach to the use of biologics for allergic diseases, including asthma, CRSwNP, atopic dermatitis and food allergy
• Evaluate for potential immunodeficiency
• Diagnose and manage patients with mast cell disorders
• Develop a management plan for beta-lactam and other drug hypersensitivities
• Incorporate shared-decision-making into clinical practice
• Discuss therapeutic options for rescue therapy in patients with asthma
• Select appropriate patients with atopic dermatitis for patch testing
EAC 2024 Update in Allergy, Asthma & Immunology
May 30 - June 2, 2024
The Breakers, Palm Beach FL
Thursday, May 30
3:30 – 4:00 Update on beta-lactam allergy, Kimberly Blumenthal, MD
4:00 – 4:30 Testing and management of inducible urticarias, Eric Oliver, MD
4:30 – 5:00 Military accession, retention, and deployment: Defining the role of the allergy consultant, Karla Adams, MD
5:00 – 5:15 Panel Discussion: Q & A
5:15 – 5:45 The use of biologics in food allergy management, Marcus Shaker, MD
5:45 – 6:15 Epinephrine: Alternate routes of administration, Michael Blaiss, MD
6:15 – 6:30 Panel Discussion: Q & A
Friday, May 31, 2024
7:45 – 8:15 CVID: Diagnosis and treatment update, Jennifer Heimall, MD
8:15 – 8:45 Mast cell disorders, HaT, POTS and EDS: Sorting fact from fiction, Jonathan Lyons, MD
8:45 – 8:55 Panel Discussion: Q & A
8:55 – 10:00 PBL: A 43-year-old woman with nasal congestion and wheezing, Ray Davis, MD, Don Bukstein, MD, Kevin Murphy, MD,
Russell Settipane, MD, Dana Wallace, MD
10:00 – 10:45 Coffee Break: Visits exhibits and posters
10:45 – 11:15 How T2-related comorbidities affect management strategies for severe asthma, Rohit Katial, MD
11:15 – 11:45 AERD: Weighing the risks/benefits of ASA desensitization vs. FESS vs. biologic, Dana Wallace, MD
11:45 – 12:15 Is it achievable to go from control to super responder to remission in asthma?, Michael Blaiss, MD
12:15 – 12:25 Panel Discussion: Q & A
1:20 – 1:50 Operationalizing shared decision making in clinical practice: How I do it, Marcus Shaker, MD
1:50 – 2:20 Angioedema without urticaria: Diagnosis, management and how to document, Aleena Banerji, MD
2:20 – 2:50 Drug hypersensitivity: Making practical use of practice parameters, Kimberly Blumenthal, MD
2:50 – 3:00 Panel Discussion: Q & A
Saturday, June 1, 2024
7:45 – 8:15 Diagnostic testing approaches for evaluating mastocytosis, Jonathan Lyons, MD
8:15 – 8:45 Atopic dermatitis: Best of guidelines and yardsticks, Mark Boguniewicz, MD
8:45 – 8:55 Panel Discussion: Q & A
8:55 – 10:00 PBL: A 18-year-old woman with occasional asthma exacerbations, Ray Davis, MD, Don Bukstein, MD, Leonard Bacharier, MD, Russell Settipane, MD, Dana Wallace, MD
10:00 – 10:45 Coffee Break: Visit exhibits and posters
10:45 – 11:45 Debate: ICS/SABA rescue for all vs. just for select asthma patients, Leonard Bacharier, MD vs. Dana Wallace, MD
11:45 – 12:15 Assessing asthma control: How best to do it, Kevin Murphy, MD
12:15 – 12:25 Panel Discussion: Q & A
1:20 – 1:50 Novel perspectives to optimize practice management, Priya Bansal, MD
1:50 – 2:00 Panel Discussion: Q & A
2:00 – 3:00 Debate: Patch testing is underutilized in atopic dermatitis, Mark Boguniewicz, MD vs. Luz Fonacier, MD
Sunday, June 2, 2024
8:15 – 8:45 AIT: How to stay current with USP 797 and practice guidelines, Maureen Peterson, MD
8:45 – 9:15 The changing economics of AIT, J. Allen Meadows, MD
9:15 – 9:45 Assessing AIT outcomes: How and why?, Maureen Peterson, MD
9:45 – 10:15 Remote asthma monitoring: How and why?, Priya Bansal, MD
10:15 – 10:30 Panel Discussion: Q & A
All identified relevant financial relationships with ineligible companies have been mitigated.
Leonard Bacharier, MD – Speaker
Speaker: Sanofi and Regeneron
Advisor: Sanofi and Regeneron, AstraZeneca, DBV Technologies, OM Pharma, Vertex, Aravax
Researcher: AstraZeneca, OM Pharma
Aleena Banerji, MD – Speaker
Researcher: Ionis, Takeda, Kalvista, Astria
Consultant: Ionis, Takeda, Kalvista, Astria, BioCryst, Intellia, CSL Behring, ADARx, Pharvaris
Priya Bansal, MD – Speaker
Advisor: AstraZeneca, GSK, Takeda, CSL Behring, Teva, Kalvista
Speaker: AstraZeneca, GSK, Sanofi/Regeneron, Takeda, CSL Behring, Teva
Consultant: AstraZeneca, GSK, Sanofi/Regeneron, Blueair
Michael Blaiss, MD – Speaker
Advisor: Sanofi, Regeneron
Speaker: Sanofi, Regeneron
Consultant: Sanofi, Regeneron, GSK, Bryn, ALK, Prollergy, Nectar, Lanier Therapeutics
Kimberly Blumenthal, MD – Speaker
Researcher: Thermo Fisher
Royalties: UpToDate
Consultant: Denali, Publix Super Market
Mark Boguniewicz, MD – Speaker
Advisor: Regeneron, Sanofi, AbbVie, Amgen, Dermavant, Eli Lilly, Incyte, Janssen, Leo Pharma, Pfizer
Researcher: Regeneron, Sanofi
Don Bukstein, MD – PBL Facilitator
Speaker: Sanofi and Regeneron
Ray Davis, MD – PBL Facilitator
Consultant: Regeneron, Sanofi, Grifols, Kalvista, AstraZeneca
Luz Fonacier, MD – Speaker
Researcher: Regeneron, Pfizer, AstraZeneca
Consultant: Regeneron, Pfizer, AbbVie, Lilly, Leo Pharma, Dermavant
William Greisner, III, MD – Planner/Moderator/Reviewer
Researcher – Allergy Therapeutics, Allakos, AstraZeneca, GSK
Jennifer Heimall, MD – Speaker
Advisor: CSL Behring, Sumitomo
Speaker: CSL Behring
Researcher: CSL Behring, ADMA, Regeneron, Sumitomo
Royalties: UpToDate
DSMB: Jasper Therapeutics
Rohit Katial, MD – Speaker
Speaker: AstraZeneca, Pharming
Advisor: AstraZeneca, Sanofi/Regeneron, GSK
Researcher: Sanofi/Regeneron
Jonathan Lyons, MD – Speaker
Consultant: HI-Bio
J. Allen Meadows, MD – Speaker
Speaker: Regeneron, Sanofi, Pfizer, Amgen
Consultant: Bryn, Takeda
Advisor: Merck
Kevin Murphy, MD – Speaker
Advisor: AstraZeneca, Sanofi/Regeneron, Pharming
Speaker AstraZeneca, Sanofi/Regeneron, GSK
Consultant: AstraZeneca, Sanofi/Regeneron
Eric Oliver, MD – Speaker
Advisor: Novartis
Researcher: Novartis, Escient
Robert Settipane, MD – Planner/Moderator
Independent Contractor: Regeneron
Russell Settipane, MD – Planner/Moderator/Speaker/Reviewer
Advisor: AbbVie, AstraZeneca, BioCryst, DBV, GSK, Pfizer, Kalvista, Pharming
Speaker: AbbVie, Amgen, AstraZeneca, BioCryst, Genentech, GSK, Regeneron, Sanofi, Takeda, Grifols, Pharming
Independent Contractor: AstraZeneca, BioCryst, DBV, Genentech, GSK, Regeneron, Takeda
Dana Wallace, MD – Speaker/Facilitator
Advisor: AbbVie, Bryn, Genentech, ARS
The following have no relevant financial relationships with ineligible companies to disclose:
Karla Adams, MD – Speaker
Joseph Bellanti, MD – Planner/Speaker
William Corrao, MD – Planner, Moderator
Ginny Loiselle – Coordinator
Katelyn Loiselle, BSN, RN – Planner
Maureen Petersen, MD – Speaker
Marcus Shaker, MD - Speaker
Kelli Wilson – Planner
Available Credit
- 16.75 AMA PRA Category 1 Credit™
- 16.75 Attendance
- 16.75 CBRN